lung cancer program (LDC)

N/A

Report date: 2025/03/20 15:19:11
NME

Base Information

Drug Namelung cancer program (LDC)
Drug Alias Nameanti-NSCLC program (Lead Discovery)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLead Discovery Center GmbH
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A